Turnstone teams up with Moffitt to race TIL cell therapies into the clinicnews2021-11-29T13:08:16+00:00November 29th, 2021|FierceBiotech|
Is molnupiravir a turkey? Merck slips out drop in efficacy of COVID-19 antiviral over Thanksgiving periodnews2021-11-29T11:19:49+00:00November 29th, 2021|FierceBiotech|
Next-gen CAR player Quell Therapeutics drives into the fast lane with major $156M roundnews2021-11-29T09:49:33+00:00November 29th, 2021|FierceBiotech|
FDA halts phase 1b Kura Oncology trial in acute myeloid leukemia following patient deathnews2021-11-24T13:47:57+00:00November 24th, 2021|FierceBiotech|
Chasing Regeneron, Pfizer posts data on $250M cardiovascular betnews2021-11-24T13:23:05+00:00November 24th, 2021|FierceBiotech|
Kymera’s first-in-class protein degrader shows potential to boost cancer immunotherapynews2021-11-24T12:10:52+00:00November 24th, 2021|FierceBiotech|
Acorda CMO hits the exit, landing Pharnext job with oversight of phase 3 neurological disorder trialnews2021-11-24T10:52:00+00:00November 24th, 2021|FierceBiotech|
Rafael resets after phase 3 flop, parting ways with 5 execs and reinstating telecom tycoon as CEOnews2021-11-23T13:03:53+00:00November 23rd, 2021|FierceBiotech|
AstraZeneca, after years of delays and spiraling costs, opens Cambridge R&D site. Will the bet pay off?news2021-11-23T10:06:14+00:00November 23rd, 2021|FierceBiotech|
Vaccibody, now Nykode, celebrates new name with a Regeneron deal worth $900M-plusnews2021-11-23T08:28:26+00:00November 23rd, 2021|FierceBiotech|
